These results showed that the combined treatment with vemurafenib and GSK126 inhibited tumor growth of PDX models more efficiently than a single treatment with vemurafenib, especially in those concurrently containing BRAF V600E mutation and EZH2 gain with no obvious toxicity. This evidence concerns the gene BRAF and neoplasm.